Search Results - "Duerinck, J"

Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma by Duerinck, J., Du Four, S., Bouttens, F., Andre, C., Verschaeve, V., Van Fraeyenhove, F., Chaskis, C., D’Haene, N., Le Mercier, M., Rogiers, A., Michotte, A., Salmon, I., Neyns, B.

“…Axitinib is a small molecule tyrosine kinase inhibitor with high affinity and specificity for the family of vascular endothelial growth factor receptors. It…”
Get full text

Systematic review of current randomised control trials in chronic subdural haematoma and proposal for an international collaborative approach by Edlmann, E., Holl, D. C., Lingsma, H. F., Bartek, J., Bartley, A., Duerinck, J., Jensen, T. S. R., Soleman, J., Shanbhag, N. C., Devi, B. Indira, Laeke, T., Rubiano, A. M., Fugleholm, K., van der Veken, J., Tisell, M., Hutchinson, P. J., Dammers, R., Kolias, A. G.

“…Background Chronic subdural haematoma (CSDH) is a pathology that is frequently encountered by neurosurgeons. Nevertheless, there is a lack of guidelines based…”
Get full text

Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma by Duerinck, J., Du Four, S., Vandervorst, F., D’Haene, N., Le Mercier, M., Michotte, A., Van Binst, A. M., Everaert, H., Salmon, I., Bouttens, F., Verschaeve, V., Neyns, B.

“…We conducted a randomized, non-comparative, multi center, phase II clinical trial in order to investigate the efficacy of axitinib, an oral small molecule…”
Get full text

Comparison of the effect of anterior and posterior neurosurgical treatment for cervical spondylotic myelopathy: a clinical outcome by Bourgonjon, B., Duerinck, J., Moens, M., D’Haens, J.

“…Cervical degenerative disease is the most common cause of acquired disability in patients over the age of 50. The incidence of cervical spondylotic myelopathy…”
Get full text

Phase II study of sunitinib malate in patients with recurrent high-grade glioma by Neyns, B., Sadones, J., Chaskis, C., Dujardin, M., Everaert, H., Lv, S., Duerinck, J., Tynninen, O., Nupponen, N., Michotte, A., De Greve, J.

“…Receptor tyrosine kinase signaling causes profound neo-angiogenesis in high-grade gliomas (HGG). The KIT , PDGFR-α , and VEGFR2 genes are frequently amplified…”
Get full text

Expression of thyroid transcription factor 1 in a chordoid glioma by Michotte, A, Van Der Veken, J, Huylebrouck, M, Duerinck, J, D'Haens, J, Hoorens, A

“…Highlights • Expression of TTF-1 (Nkx2-1) is shown for the first time in a chordoid glioma. • Involvement of TTF-1 in signalling pathways of chordoid glioma…”
Get full text

Neuro-oncological augmented reality planning (NOA-p) by Van Gestel, F., Frantz, T., Neuville, Q., Klein, S., Bruneau, M., Jansen, B., Scheerlinck, T., Vandemeulebroucke, J., Duerinck, J.

Get full text

Prognostic value of 0-(2-[18F]-fluoroethyl)-L-tyrosine PET in patients with recurrent GBM by Geens, W., Du Four, S., Van Laere, S., Schwarze, J.K., Awada, G., Tijtgat, J., Bruneau, M., Everaert, H., Neyns, B., Duerinck, J.

Get full text

The effect of augmented reality on the learning curve of external ventricular drain placement by Van Gestel, F., Frantz, T., Vannerom, C., Verhellen, A., Gallagher, A.G., Elprama, S.A., Jacobs, A., Buyl, R., Bruneau, M., Jansen, B., Vandemeulebroucke, J., Scheerlinck, T., Duerinck, J.

Get full text

O10.07 RANDOMIZED PHASE II STUDY OF AXITINIB VS. STANDARD OF CARE IN PATIENTS WITH RECURRENT GLIOBLASTOMA by Duerinck, J., Du Four, S., Bouttens, F., Verschaeve, V., Everaert, H., De Raedt, S., Van Binst, A., Neyns, B.

“…INTRODUCTION: Glioblastoma (GB) associated neo-angiogenesis is mediated by vascular endothelial growth factor receptor (VEGFR) signal transduction. Axitinib is…”
Get full text

P16.09 VALUE OF FET-PET EVALUATION IN PATIENTS TREATED WITH AXITINIB by Duerinck, J., Du Four, S., De Raedt, S., Everaert, H., Van Binst, A., Neyns, B.

“…INTRODUCTION: VEGF/VEGFR targeted therapy for recurrent glioblastoma (rGB) normalizes tumour vasculature and restores the blood-brain barrier (BBB), resulting…”
Get full text

Spinal Epidural Hematoma Misdiagnosed as Myocardial Infarction by Van Der Veken, J, Van Rompaey, K, Duerinck, J, Ampe, B, D'Haens, J

Get full text

Erections Upon Walking. A Less Known Symptom of Lumbar Canal Stenosis by Duerinck, J, Van Rompaey, K, Van Der Veken, J, Du Four, S, Ampe, B, Moens, M, D'Haens, J

Get full text

Twiddler's Syndrome Complicating Neuromodulation Systems For Chronic Pain by Moens, M, De Smedt, A, Duerinck, J, D'Haens, J, Brouns, R

Get full text

An Unusual Case of Dural Plasmacytoma by Duerinck, J, Van Rompaey, K, Moens, M, Michotte, A, Schots, R, D'Haens, J

Get full text

An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals by D'Haens, J., Neyns, Bart, Huylebrouck, M., Lv, S., Duerinck, Johnny, Van Binst, A., Salmon, I., De Greve, J., De Witte, O., Luce, S., Michotte, Alex

“…Background. Bevacizumab (BEV), a humanized immunoglobulin G1 monoclonal antibody that inhibits VEGF has demonstrated activity against recurrent high-grade…”
Get full text

OS03.5.A A PHASE I CLINICAL TRIAL ON THE INTRACRANIAL ADMINISTRATION OF AUTOLOGOUS CD1C(BDCA-1)+ /CD141(BDCA-3)+ MYELOID DENDRITIC CELLS IN COMBINATION WITH IPILIMUMAB AND NIVOLUMAB IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA by Duerinck, J, Lescrauwaet, L, Dirven, I, Del’haye, J, Cammaert, M, Geens, W, Geeraerts, X, Stevens, L, Brock, S, Kockx, M, Everaert, H, Vanbinst, a, Tuyaerts, S, Neyns, B

“…Abstract BACKGROUND Intracranial (iCran) administration of the PD-1 and CTLA-4 blocking monoclonal antibodies nivolumab (NIVO) and ipilimumab (IPI) at the time…”
Get full text

OS03.4.A REPEATED INTRACRANIAL ADMINISTRATION OF ANTI-PD-1 ALONE OR IN COMBINATION WITH ANTI-CTLA-4 IMMUNE CHECKPOINT-BLOCKING MONOCLONAL ANTIBODIES IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA by Lescrauwaet, L, Dirven, I, Del’haye, J, Geens, W, Geeraerts, X, Stevens, L, Brock, S, Kockx, M, Seynaeve, L, Everaert, H, Vanbinst, a, Tuyaerts, S, Neyns, B, Duerinck, J

“…Abstract BACKGROUND Recurrent high-grade glioma (rHGG) is an invariably fatal malignancy, currently lacking life-prolonging treatment options. Systemic…”
Get full text

P07.02.B Neuro-oncological augmented reality planning (NOA-p) by Van Gestel, F, Frantz, T, Neuville, Q, Klein, S, Bruneau, M, Jansen, B, Scheerlinck, T, Vandemeulebroucke, J, Duerinck, J

“…Abstract Background When preparing for the resection of an intracranial lesion, neuronavigation with a tracked pointer is most often used to determine lesion…”
Get full text

P06.18.B OVERVIEW OF THE GLITIPNI TRIAL - LOCAL ADMINISTRATION OF IMMUNE CHECKPOINT INHIBITION AND/OR DENDRITIC CELLS FOLLOWING RESECTION OF RECURRENT GLIOBLASTOMA by Duerinck, J, Tijtgat, J, Dirven, I, Geens, W, Brock, S, Michotte, A, Geeraerts, X, Stevens, L, Thuyaerts, S, Everaert, H, Vanbinst, A, Bruneau, M, Rogiers, A, Neyns, B

“…Abstract BACKGROUND Intravenous (IV) administration of the Immune checkpoint inhibitor (ICI) nivolumab (NIVO) for recurrent glioblastoma (rGB) has proven…”
Get full text